Edgewise Therapeutics (EWTX) Payables (2020 - 2026)
Edgewise Therapeutics (EWTX) posted Payables of $7.3 million for Q1 2026, up 21.43% sequentially from $6.0 million in Q4 2025, and down 17.02% YoY from $8.8 million in Q1 2025.
Edgewise Therapeutics (EWTX) Payables (2020 - 2026) Analysis & Trends
Edgewise Therapeutics has reported Payables for 7 years, with the latest figure at $7.3 million in Q1 2026.
- Quarterly Payables fell 17.02% year-over-year to $7.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.3 million (down 17.02% YoY) and the FY2025 annual result came in at $6.0 million, up 7.65% from the prior year.
- Payables climbed to $7.3 million in Q1 2026 per EWTX's latest filing, from $6.0 million in the prior quarter.
- Over five years, Payables peaked at $8.8 million in Q1 2025 and troughed at $2.8 million in Q2 2022.
- A 5-year average of $5.7 million and a median of $5.6 million in 2024 frame the typical range for Payables.
- The sharpest annual moves came in 2022 and 2023: Payables soared 229.43% in 2022, then slumped 34.07% in 2023.
- Over 5 years, Payables stood at $6.1 million in 2022, then sank by 34.07% to $4.0 million in 2023, then soared by 38.61% to $5.6 million in 2024, then grew by 7.65% to $6.0 million in 2025, then rose by 21.43% to $7.3 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $7.3 million, $6.0 million, and $6.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Edgewise Therapeutics | 4.76 Bn | 4.76 Bn | - | 4.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.67 Mn |
| Mar 31, 2026 | 7.29 Mn |
| Dec 31, 2025 | 6.01 Mn |
| Sep 30, 2025 | 6.16 Mn |
| Jun 30, 2025 | 8.32 Mn |
| Mar 31, 2025 | 8.79 Mn |
| Dec 31, 2024 | 5.58 Mn |
| Sep 30, 2024 | 5.65 Mn |
| Jun 30, 2024 | 6.80 Mn |
| Mar 31, 2024 | 4.72 Mn |
| Dec 31, 2023 | 4.03 Mn |
| Sep 30, 2023 | 5.32 Mn |
| Jun 30, 2023 | 3.78 Mn |
| Mar 31, 2023 | 3.88 Mn |
| Dec 31, 2022 | 6.11 Mn |
| Sep 30, 2022 | 5.76 Mn |
| Jun 30, 2022 | 2.83 Mn |
| Mar 31, 2022 | 5.34 Mn |
| Dec 31, 2021 | 3.84 Mn |
| Sep 30, 2021 | 2.29 Mn |